We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. announced that it has dosed first patients in a phase II study to evaluate its key pipeline candidate — etrasimod — as a potential treatment for moderate-to-severe alopecia areata. The study will evaluate 2mg dose of the candidate for efficacy and safety over 24 weeks.
The primary endpoint of the phase II study is percent change in Severity of Alopecia Tool (“SALT”) score from baseline. Data from the study is anticipated in 2021.
The candidate has demonstrated potential to reduce inflammation and restore hair growth in earlier stage studies.
Shares of Arena have gained 50.5% year to date compared with the industry’s increase of 2.7%.
Alopecia areata is an autoimmune dermatologic condition that results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients. Pfizer (PFE - Free Report) is another company developing an oral JAK3 inhibitor candidate, PF-06651600 for Alopecia areata in a pivotal study.
Apart from alopecia areata, Arena is developing etrasimod in other indications as well. The candidate is presently in late-stage development for ulcerative colitis (“UC”). Arena is currently enrolling patients in two pivotal phase III studies — ELEVATE UC 52 and ELEVATE UC 12 — evaluating etrasimod for treating moderately-to-severely active UC.
A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis (“AD”). Data from the study is expected later this year. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn's disease. The company has plans to start a mid-stage study to evaluate the candidate for eosinophilic esophagitis, a gastro-intestinal disease by year-end.
Arena has another key pipeline candidate, olonarib. The phase II CAPTIVATE study is evaluating olonarib as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected later this year.
We note that Arena is progressing well with its key pipeline candidates. However, the company will face stiff competition from multiple approved drugs in their targeted indications. There are several drugs approved for treating UC including AbbVie’s (ABBV - Free Report) multi-billion dollar drug, Humira. Sanofi/Regeneron’s (REGN - Free Report) Dupixent is one of the top drugs approved for treating AD. Moreover, olonarib, following a potential approval, will compete with AbbVie/Ironwood Pharma’s Linzess.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
Arena Pharmaceuticals, Inc. announced that it has dosed first patients in a phase II study to evaluate its key pipeline candidate — etrasimod — as a potential treatment for moderate-to-severe alopecia areata. The study will evaluate 2mg dose of the candidate for efficacy and safety over 24 weeks.
The primary endpoint of the phase II study is percent change in Severity of Alopecia Tool (“SALT”) score from baseline. Data from the study is anticipated in 2021.
The candidate has demonstrated potential to reduce inflammation and restore hair growth in earlier stage studies.
Shares of Arena have gained 50.5% year to date compared with the industry’s increase of 2.7%.
Alopecia areata is an autoimmune dermatologic condition that results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients. Pfizer (PFE - Free Report) is another company developing an oral JAK3 inhibitor candidate, PF-06651600 for Alopecia areata in a pivotal study.
Apart from alopecia areata, Arena is developing etrasimod in other indications as well. The candidate is presently in late-stage development for ulcerative colitis (“UC”). Arena is currently enrolling patients in two pivotal phase III studies — ELEVATE UC 52 and ELEVATE UC 12 — evaluating etrasimod for treating moderately-to-severely active UC.
A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis (“AD”). Data from the study is expected later this year. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn's disease. The company has plans to start a mid-stage study to evaluate the candidate for eosinophilic esophagitis, a gastro-intestinal disease by year-end.
Arena has another key pipeline candidate, olonarib. The phase II CAPTIVATE study is evaluating olonarib as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected later this year.
We note that Arena is progressing well with its key pipeline candidates. However, the company will face stiff competition from multiple approved drugs in their targeted indications. There are several drugs approved for treating UC including AbbVie’s (ABBV - Free Report) multi-billion dollar drug, Humira. Sanofi/Regeneron’s (REGN - Free Report) Dupixent is one of the top drugs approved for treating AD. Moreover, olonarib, following a potential approval, will compete with AbbVie/Ironwood Pharma’s Linzess.
Arena Pharmaceuticals, Inc. Price
Arena Pharmaceuticals, Inc. price | Arena Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Arena is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>